Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Methohexital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.33 |
| ▸ | GABRG2 known ✓ | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 known ✓ | P28472 | 3/20 | 0.33 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methohexital SCHEMBL80730 | 0.99 | MMP9 (0.42) | MMP9NR1I2CYP3A4GABRA1GABRG2 | |
| Methohexital SCHEMBL80729 | 0.99 | MMP9 (0.42) | MMP9NR1I2CYP3A4GABRA1GABRG2 | |
| Methohexital SCHEMBL11111822 | 0.99 | MMP9 (0.42) | MMP9NR1I2CYP3A4GABRA1GABRG2 | |
| Methohexital SCHEMBL19420179 | 0.99 | MMP9 (0.42) | MMP9NR1I2CYP3A4GABRA1GABRG2 | |
| Methohexital SCHEMBL20980055 | 0.99 | MMP9 (0.42) | MMP9NR1I2CYP3A4GABRA1GABRG2 | |
| SCHEMBL10581308 | 0.88 | MMP9 (0.39) | MMP9NR1I2CYP3A4LMNA | |
| Methohexital SCHEMBL1003787 | 0.85 | LMNA (0.59) | MMP9GABRA1GABRG2GABRB3GABRB2 | |
| Methohexital SCHEMBL4837768 | 0.85 | MMP9 (0.33) | MMP9GABRA1GABRG2GABRB3GABRB2 | |
| Methohexital SCHEMBL13724704 | 0.85 | GABRA1 (0.33) | MMP9GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL17471557 | 0.84 | MMP9 (0.35) | MMP9NR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414078-B2 | Oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060111339-A1 | Novel oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA | 2006-05-25 | — | — | US | disclosed |
| US-7026358-B2 | Oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040133012-A1 | Novel oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-07-08 | — | — | US | disclosed |
| EP-0788308-B1 | POLYMERIC WOUND HEALING ACCELERATORS | UNIV AKRON (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0788308-A4 | POLYMERIC WOUND HEALING ACCELERATORS | UNIV AKRON (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0788308-A1 | POLYMERIC WOUND HEALING ACCELERATORS | The University of Akron (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5519020-A | POLYMER ADDUCTS WHICH RELEASE NITRIC OXIDE | THE UNIVERSITY OF AKRON (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1996013164-A1 | POLYMERIC WOUND HEALING ACCELERATORS | UNIVERSITY OF AKRON, THE (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0080779-B1 | 3-BENZAZEPINES AS ALPHA-2 ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4496558-A | Pharmaceutical compositions and methods for producing alpha antagonism | SMITHKLINE BECKMAN CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| US-4465677-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0108170-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0080779-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-08 | — | — | EP | disclosed |
| US-4017619-A | MIXTURE OF KETAMINE HYDROCHLORIDE AND DIAZEPAM | BURNAP RAYMOND W | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111339-A1 | Novel oral general anesthetics and metabolitically resistant anticonvulsants | SULT2A1, GRIK5, GRIN2D | GABRA1 51/4885GABRG2 121/4885GABRB3 92/4885 |
| US-20040133012-A1 | Novel oral general anesthetics and metabolitically resistant anticonvulsants | SULT2A1, GRIK5, GRIN2D | GABRA1 51/4885GABRG2 121/4885GABRB3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.